Progyny, Inc. (PGNY) — SEC Filings
Progyny, Inc. (PGNY) — 39 SEC filings. Latest: 10-Q (May 8, 2026). Includes 17 8-K, 9 SC 13G/A, 7 10-Q.
View Progyny, Inc. on SEC EDGAR
Overview
Progyny, Inc. (PGNY) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 17, 2025: On December 12, 2025, Progyny, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the filing announced the election of new directors and adjustments to compensatory arrangements for certain officers. The report was filed with the SEC on Dec
Sentiment Summary
Across 39 filings, the sentiment breakdown is: 38 neutral, 1 mixed. The dominant filing sentiment for Progyny, Inc. is neutral.
Filing Type Overview
Progyny, Inc. (PGNY) has filed 7 10-Q, 1 ARS, 1 DEFA14A, 17 8-K, 2 10-K, 1 8-K/A, 9 SC 13G/A, 1 DEF 14A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (39)
Risk Profile
Risk Assessment: Of PGNY's 26 recent filings, 0 were flagged as high-risk, 3 as medium-risk, and 23 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $970.258M |
| Net Income | $46.035M |
| EPS | $0.51 |
| Debt-to-Equity | 0.42 |
| Cash Position | $133.982M |
| Operating Margin | 7.2% |
| Total Assets | $795.227M |
| Total Debt | $0 |
Key Executives
- Dr. Mark J. Ratner
- Ms. Karen M. King
- Dr. David S. Chen
- Ms. Karen L. Koster
Industry Context
Progyny operates in the rapidly growing fertility and family building benefits management sector. The industry is characterized by increasing demand for comprehensive solutions that support employees through various stages of family formation. Key trends include employer focus on holistic wellness, the integration of technology, and the expansion of services beyond traditional fertility treatments.
Top Tags
8-K (6) · financial-condition (6) · 10-Q (4) · financials (4) · operations (3) · 8-k (3) · Progyny (3) · corporate-governance (2) · executive-compensation (2) · Healthcare Services (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 001-39100 | Identifies Progyny's filings with the SEC. |
| IRS Employer Identification No. | 27-2220139 | Progyny's tax identification number. |
| Revenue for Nine Months Ended Sep 30, 2025 | $970.258M | Increased from $868.790 million in 2024, an 11.7% increase. |
| Net Income for Nine Months Ended Sep 30, 2025 | $46.035M | Increased from $43.804 million in 2024, a 5.1% increase. |
| Gross Profit for Nine Months Ended Sep 30, 2025 | $227.603M | Increased from $189.931 million in 2024. |
| Cash and Cash Equivalents as of Sep 30, 2025 | $133.982M | Decreased from $162.314 million as of Dec 31, 2024. |
| Marketable Securities as of Sep 30, 2025 | $211.225M | Increased significantly from $65.640 million as of Dec 31, 2024. |
| Net Cash Provided by Operating Activities for Nine Months Ended Sep 30, 2025 | $155.989M | Increased from $126.941 million in 2024. |
| Net Cash Used in Investing Activities for Nine Months Ended Sep 30, 2025 | $167.269M | Shifted from $120.802 million provided in 2024, primarily due to increased marketable securities purchases. |
| Shares of Common Stock Outstanding as of Oct 31, 2025 | 86,211,654 | Reflects the total shares outstanding. |
| Fiscal Year End | 2024 | Reporting period for the 10-K |
| Prior Fiscal Year | 2023 | For comparative financial analysis |
| Period End Date | 2024-09-30 | Indicates the end of the reporting quarter |
| Filing Date | 2024-11-12 | Date the report was submitted to the SEC |
| Data Range | 2020-2023 | Years covered for stock awards and options data |
Frequently Asked Questions
What are the latest SEC filings for Progyny, Inc. (PGNY)?
Progyny, Inc. has 39 recent SEC filings from Jan 2024 to May 2026, including 17 8-K, 9 SC 13G/A, 7 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PGNY filings?
Across 39 filings, the sentiment breakdown is: 38 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Progyny, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Progyny, Inc. (PGNY) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Progyny, Inc.?
Key financial highlights from Progyny, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PGNY?
The investment thesis for PGNY includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Progyny, Inc.?
Key executives identified across Progyny, Inc.'s filings include Dr. Mark J. Ratner, Ms. Karen M. King, Dr. David S. Chen, Ms. Karen L. Koster.
What are the main risk factors for Progyny, Inc. stock?
Of PGNY's 26 assessed filings, 0 were flagged high-risk, 3 medium-risk, and 23 low-risk.
What are recent predictions and forward guidance from Progyny, Inc.?
Forward guidance and predictions for Progyny, Inc. are extracted from SEC filings as they are enriched.